Pregnancy, Infection, Surgery and Other Medical Conditions
Prepare for pregnancy, vaccination, infection and surgery with drug-specific plans and coordinated care.
All chapters in this collection
Understanding the diagnosis
- 1. Peripheral SpA, Undifferentiated SpA and a Working Diagnosis
- 2. Joints, Entheses and Dactylitis: Understanding the Peripheral Pattern
- 3. How the Diagnosis Is Built
- 4. New Symptoms: What Changes the Picture and When Not to Wait
Tests and imaging
- 5. Blood Tests and HLA-B27: What They Can and Cannot Tell You
- 6. Ultrasound, MRI, X-ray and Joint Aspiration: Choosing the Right Test
Treatment decisions
- 7. What Are We Actually Trying to Improve?
- 8. NSAIDs, Local Treatment and Conventional DMARDs
- 9. When Targeted Therapy Enters the Discussion
Daily life and follow-up
- 10. Movement, Feet, Hands, Work and Everyday Load
- 11. How Do We Know Treatment Is Working?
- 12. Pregnancy, Infection, Surgery and Other Medical Conditions
When the picture changes
- 13. Why the Diagnosis May Change
- 14. When Pain, Examination, Blood Tests and Imaging Disagree
- 15. Remission, Treatment Reduction and Long-Term Outlook
Research and future care
A medicine that is appropriate today may need review when circumstances change. Pregnancy planning, infection, surgery and a new medical condition each raise different questions. The safest preparation is a written plan for the particular drug and situation, rather than a universal rule to stop everything.
Discuss pregnancy before treatment becomes urgent
If pregnancy is possible or planned, bring it into treatment discussions early. The aim is to maintain disease control using a compatible regimen and to avoid unplanned exposure to drugs that require advance changes. Stopping all treatment can also have consequences if inflammation returns.
Pregnancy recommendations depend on the exact medicine, the person taking it, the stage of pregnancy and the disease context. Advice for the pregnant patient may differ from advice for a partner contributing sperm. Tell the team which situation applies rather than relying on a generic warning attached to a drug name.
Methotrexate and leflunomide require particular reproductive planning for someone who may become pregnant. Other medicines can be compatible in appropriate circumstances. If an unexpected pregnancy occurs during treatment, contact the prescribing and obstetric teams promptly for individual advice; do not assume the outcome from an internet list.
Breastfeeding and the postpartum period
Medication compatibility during breastfeeding is a separate question from compatibility during pregnancy. Plan before delivery where possible, including what happens if disease activity increases afterward. Current guidance supports several treatment options, but the exact regimen should be confirmed for you.
Tell the infant’s clinician about relevant medication exposure during pregnancy because it may affect the planning of particular infant vaccines. The advice is drug- and vaccine-specific. Do not cancel all infant vaccinations on the basis of a broad statement about biologics.
Vaccination belongs in routine planning
Review vaccines before starting immune-suppressing treatment and periodically thereafter. Some vaccines have broader indications in people receiving these medicines. Timing may affect the immune response, and live vaccines require particular planning.
The decision to adjust a drug around vaccination depends on that drug, the vaccine and disease activity. Obtain instructions from the prescribing team instead of borrowing a schedule from another patient. Keep a vaccination record that all your clinicians can see.
Have an infection contact plan
Ask whom to contact for fever, shingles, a significant new cough or another suspected infection, and what to do before the next scheduled dose. The response to a mild self-limited illness may differ from the response to a serious infection requiring treatment.
Emergency symptoms take priority over medication questions. Severe breathlessness, confusion, collapse or rapidly worsening severe illness needs emergency assessment. A newly hot swollen joint also needs urgent evaluation. The urgent-symptom chapter provides the practical distinctions.
Surgery requires coordination
Tell the surgeon and rheumatologist about planned procedures early. Provide the actual drug names, dosing intervals, last administration dates and glucocorticoid use. The plan balances infection and wound-healing concerns against the risk of uncontrolled disease.
Published perioperative recommendations are often written for specific procedures, such as elective hip or knee replacement. They should not be applied mechanically to every operation or minor procedure. Clarify who gives the final medication instructions, when treatment may resume, and how postoperative concerns will be reviewed.
Kidney, liver and cardiovascular conditions can change the plan
Kidney function can affect the safety of NSAIDs and other medicines. Liver disease, alcohol exposure and interacting drugs may affect conventional DMARD choices. Cardiovascular or clotting history can influence the discussion of selected targeted therapies.
Bring over-the-counter products and supplements into the medication review. A new prescription from another clinician may matter even when it is unrelated to arthritis. If illness causes dehydration or reduced intake, ask whether your established plan needs adjustment.
Keep one current list and clear responsibilities
A concise medication list should show what you actually take, not only what has ever been prescribed. Include allergies, recent changes, relevant specialist diagnoses and the contact route for urgent questions. Ask which team is responsible for laboratory monitoring and who will communicate abnormal results.
The purpose is to make transitions safer while preserving disease control. You should leave a discussion with an actionable plan for your circumstances, not the burden of deciding alone which risk matters most. Targeted therapy and conventional treatment explain why those plans differ by medicine.
Sources and further reading
- EULAR recommendations on antirheumatic drugs in reproduction, pregnancy and lactation: 2024 update, published 2025
- ACR guideline for reproductive health in rheumatic and musculoskeletal diseases, 2020
- ACR guideline for vaccinations in rheumatic and musculoskeletal diseases, 2022
- ACR/AAHKS perioperative management guidance, 2022
- NIDDK: Keeping kidneys safe—smart choices about medicines
- NHS: Sepsis